Beatrice Taurelli Salimbeni

An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)

P. Marchetti, M. Roberto, M. Panebianco, 2021, Current oncology.

Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC

M. Filetti, P. Marchetti, R. Giusti, 2020, Cancer reports.

Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape

G. Curigliano, D. Trapani, J. Uliano, 2022, Expert review of clinical pharmacology.

Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance

G. Curigliano, F. Puglisi, Beatrice Taurelli Salimbeni, 2022, Expert opinion on pharmacotherapy.

The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

G. Curigliano, P. Zagami, C. Valenza, 2022, Expert opinion on investigational drugs.

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment

G. Curigliano, D. Trapani, G. Antonarelli, 2023, Cancers.

The CDK4/6 Inhibitors Biomarker Landscape: the most Relevant Biomarkers of Response or Resistance for Further Research and Potential Clinical Utility.

C. Criscitiello, G. Curigliano, A. Esposito, 2023, Critical reviews in oncology/hematology.

PARP Inhibitors for Breast Cancer Treatment: A Review.

C. Criscitiello, G. Bianchini, F. Giugliano, 2024, JAMA oncology.